Image credit: Kimimasa Mayama/​EPA/​Shutterstock
March 18, 2020 03:57 PM EDTUpdated 04:17 PM
R&D
China
Coronavirus

A Japan­ese flu drug gets up­beat re­views in Chi­na for blunt­ing the im­pact of Covid-19 — and that is bol­ster­ing Gilead­'s case for remde­sivir

John Carroll

Editor & Founder

We’re start­ing to get the first round of da­ta on drugs be­ing used to rein in the dev­as­tat­ing out­break of Covid-19 in Chi­na. And one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times